Menu Close

Trending

Diving deeper into AI discovery, Sanofi signs 5-drug deal with Atomwise
GSK gets June 2023 FDA decision date for momelotinib
End of the line for Sanofi’s SERD amcenestrant as it fails first-line trial
Key Presentations at the Medical Devices & IVD Conference Released
Respiratory Monitoring & AI Technologies

Rett Syndrome

Illustration of a nerve cell

News/ News/ R&D/ Top stories

Newron’s shares dive after rare disease drug failure

, , , , 0 Comment

Newron’s share price has collapsed after the biotech axed development of its drug sarizotan for the rare genetic brain disorder Rett Syndrome following the failure of a key trial. 

X
Newron’s shares dive after rare disease drug failure
https://pharmaphorum.com/news/newrons-shares-dive-after-rare-disease-drug-failure/

Login

CONTINUE TO SITE >
X
Close in 10 seconds